Results 141 to 150 of about 28,326 (256)

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

Cancer Science, EarlyView.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Hisao Higo, Kammei Rai, Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Ryohei Katayama, Kadoaki Ohashi   +22 more
wiley   +1 more source

Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study

Molecular Oncology
Patients with gastro‐intestinal stromal tumors (GISTs) undergoing tyrosine kinase inhibitor therapy are monitored with regular computed tomography (CT) scans, exposing patients to cumulative radiation. This exploratory study aimed to evaluate circulating
Roos F. Bleckman, Charlotte M. S. C. Haag, Naomi Rifaela, Gerrieke Beukema, Ron H. J. Mathijssen, Neeltje Steeghs, Hans Gelderblom, Ingrid M. E. Desar, Arjen Cleven, Arja terElst, Ed Schuuring, Anna K. L. Reyners   +11 more
doaj   +1 more source

Biopsy of Iris and Anterior Chamber Tumours: Fine Needle, Minimally Invasive and Excision Techniques ‐ Review

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Several benign, inflammatory and malignant lesions can present as iris or anterior chamber masses, including iris naevi, cysts, adenomas, leiomyomas, nodules, vascular tumours, melanomas, metastases, as well as iris and pigment epithelium adenocarcinomas. Fortunately, benign iris lesions are much more common than malignant tumours and many can
Charles N. J. McGhee, Joevy Z. Lim, Peter W. Hadden, Jie Zhang   +3 more
wiley   +1 more source

The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis

npj Precision Oncology
Circulating tumor DNA (ctDNA) provides a minimally invasive tool for assessing tumor burden and genetic evolution in diffuse large B-cell lymphoma (DLBCL).
Shayan Forghani, Amirhossein Shahsavand, Reza Samiee, Mohammadamin Kharaghani, Azadeh Kiumarsi, Fatemeh Mahdavi Sabet, Saba Akbarzadeh, Sajjad Fattahniya, Mohammadreza Rostami, Soroush Rad, Amir Hossein Mirhosseini, Tahereh Rostami, Ghasem Janbabai   +12 more
doaj   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques

Cancer Management and Research
Wenlong Qi,1 Lin Tian,2 Jianan Xu,2 Zhenyu Li,2 Tan Wang2 1Changchun University of Traditional Chinese Medicine, Changchun, Jilin, 130000, People’s Republic of China; 2Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun,
Qi W, Tian L, Xu J, Li Z, Wang T
doaj  

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Patient acceptability of ctDNA testing in endometrial cancer follow-up

, 2020
Objective: Circulating tumour DNA (ctDNA) is emerging as a potential option to detect disease recurrence in many cancer types however, ensuring patient acceptability of changing clinical practice and the introduction of new technology is paramount.
DS Guttery (7628663), A Relton (10010771), D Gorsia (10010774), EL Moss (7710245), A Collins (7952654), Hilary McDermott (1254831)   +5 more
core  

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source